18F-FDG PET/CT and melanoma: Staging, immune modulation and mutation-targeted therapy assessment, and prognosis

Powell Perng, Charles Marcus, Rathan M. Subramaniam

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalAmerican Journal of Roentgenology
Volume205
Issue number2
DOIs
StatePublished - Jan 1 2015

Keywords

  • FDG PET/CT
  • Immune modulation therapy
  • Melanoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '<sup>18</sup>F-FDG PET/CT and melanoma: Staging, immune modulation and mutation-targeted therapy assessment, and prognosis'. Together they form a unique fingerprint.

Cite this